Difesa Capital Management, LP Biomarin Pharmaceutical Inc Transaction History

Difesa Capital Management, LP

  • $0
  • Q4 2023

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$86.68 - $100.3 $190,696 - $220,660
-2,200 Reduced 19.21%
9,250 $801,000
Q1 2023

May 15, 2023
BUY
$87.74 - $117.27 $39,483 - $52,771
450 Added 4.09%
11,450 $1.11 Million
Q4 2022

Feb 14, 2023
BUY
$80.93 - $108.63 $647,440 - $869,040
8,000 Added 266.67%
11,000 $1.14 Million
Q3 2022

Nov 14, 2022
BUY
$82.16 - $96.94 $20,540 - $24,235
250 Added 9.09%
3,000 $254,000
Q2 2022

Aug 12, 2022
BUY
$71.48 - $86.85 $196,570 - $238,837
2,750 New
2,750 $228,000

Others Institutions Holding BMRN

# of Institutions
637
Shares Held
177M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.5B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Difesa Capital Management, LP Portfolio

Follow Difesa Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Difesa Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Difesa Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email